21 April 2023 - Eli Lilly expects the US Medicare health plan to back down from strict coverage limits on new Alzheimer's drugs as more evidence emerges in coming weeks showing that clearing amyloid brain plaques can help patients.

Lilly plans to release results from a trial of its experimental amyloid-targeting drug donanemab before the end of June.

Read Reuters article